Abstract. Puromycin was injected bitemporally in mice one day after training in a Y-maze. Eight days later various psychotropic drugs were injected intraperitoneally or subcutaneously at maximum tolerable doses. Ten days after the drug injection the mice were tested for their memory of the maze-learning. Memory was lost in control animals injected with saline but restored in most of the animals injected with imipramine, tranylcypromine, or D-amphetamine. Some indication of restoration was observed after injection of reserpine or Ldopa. These results suggest that the blockage caused by puromycin is due to adsorption of peptidyl-puromycin to adrenergic sites and that these sites may be involved in the memory trace.
For the first three days after training, memory of Y-maze learning in mice is blocked by bitemporal injections of puromycin that primarily involve the hippocampal areas. The change in behavior is not attributable to lack of ability or motivation to perform, since the mice usually retrain readily. Also, mice trained initially to one arm of the Y-maze, retrained three weeks later to the opposite arm, and injected bitemporally with puromycin 1 day later forget their most recent training and revert with a high level of performance to the first behavior pattern.1 In these circumstances the loss of memory caused by puromycin cannot be attributed to its inhibition of protein synthesis; no such effect is observed when acetoxycycloheximide or a mixture of puromycin and acetoxycycloheximide is substituted for the puromycin even though these injections produce a more drastic and longer-lasting inhibition of protein synthesis. The blockage caused by puromycin can be removed by intracerebral injections of several inorganic solutions; thus, it is apparent that puromycin does not destroy the memory pattern but suppresses its expression.3' 4 Radioactive puromycin has been found to remain in the brain for prolonged periods (held as peptidyl-puromycin5) and is presently assumed to be the blocking agent.
The evidence that norepinephrine influences affective states, possibly by acting as a modulator otI cholinergic systems, has been summarized.6 In addition, drugs reducing the level of norepiniephrine (reserpine and alpha-methyl-paratyrosine) can cause a temporary failure to perform a well-learned conditioned avoidance response.7' 8 The suggestion has been made that the biogenic amines do in fact play an important role in the processes responsible for memory.9 Some evidence to support this suggestion appears in the effect of reserpine which causes a permanent reduction in performance when injected immediately after training. 10 The similarity of the chemical structure of the 0-methyl tyrosine moiety of puromycin to norepinephrine and various mescalin-like drugs suggests a possible relationship of these otherwise unrelated sets of phenomena. Possibly, norepinephrine is important in the establishment and recall of memory traces and the puromycin acts in part by blocking adrenergic sites. If so, it might be possible to reverse the block established by puromycin by use of drugs known to influence the adrenergic system. Experiments were performed to test this possibility.
Mice were trained to a criterion of 9/10 in a single session on day 1 in a Ymaze. On day 2, according to their weight, they were injected bitemporally at each site with 90 or 120 ,ug of puromycin 2HCl (neutralized with NaOH) dissolved in 12 ,Al of saline. Intraperitoneal or subcutaneous injection of drugs was given on day 10. On day 18, when the mice had recovered from the adverse effect of the drugs, they were tested to determine their memory of training. A final test of retention of relearning was made 2 weeks later. The procedures for training, injecting puromycin, and retention testing have been described in detail.' Furthermore, this technique for disruption of memory by puromycin has been in use for eight years and has resulted in consistent loss of memory.
The following drugs were used in an attempt to restore memory blocked by puromycin: L-Dopa was chosen on the chance that it or its metabolic products, dopamine and norepinephrine," might displace puromycin bound to adrenergic sites.
Reserpine was chosen because of its action in releasing norepinephrine from storage vesicles.'2 Its further action in depleting the level of norepinephrine would not be expected to be useful in displacing puromycin.
Imipramine was selected because of its action in blocking the synaptic uptake of norepinephrine,'3 presumably by competing with norepinephrine for the uptake sites. It might consequently be effective in displacing puromycin.
D-Amphetamine was used as it causes marked changes in the central nervous system possibly by mimicking norepinephrine, by releasing norepinephrine, by inhibiting monamine oxidase, by inhibiting re-uptake of norepinephrine, or by other yet unrecognized actions. 13 Tranylcypromine is a monamine oxidase inhibitor and hence could be expected to raise the level of norepinephrine which in turn might displace puromycin. In addition, it may discharge norepinephrine and may act like imipramine in interfering with the re-uptake of norepinephrine. 14 These drugs were injected in an amount only slightly below the lethal limit as roughly estimated in preliminary tests. Other tests showed that the drugs had no effect on the memory of mice that had not received puromycin.
The results are given in Table 1 . In accord with previous experiments, the control group showed complete loss of memory. Since the drugs were used at a high dosage, a number of deaths occurred. Among the survivors, however, recovery, as judged by cage and maze behavior, was complete 8 days after treatment. As shown in the table, restoration of memory following injection of imipramine, tranylcypromine, and D-amphetamine was striking. Two groups of mice were treated with these drugs at different times and the results were highly consistent. Reserpine and L-dopa on their first trial gave a relatively weak indication of restoring memory and were not tested further. Three mice used in these experiments had impaired memory on their final retention tests; the remainder showed retention of relearning at a high level. In spite of the limited number of mice tested, we believe that these experiments are sufficient to establish the efficacy of imipramine, D-amphetamine, and tranylcypromine in restoring the memory of mice treated with puromycin. In view of the consistent amnesia produced by puromycin we consider that even the partial restoration caused by reserpine and L-dopa may be significant. Thus, a group of drugs of widely different chemical structure which share the ability to cause drastic changes in the adrenergic system also appear to share the ability to restore or to improve memory blocked by puromycin.
This result suggests in turn; (a) Puromycin peptides may be absorbed to adrenergic sites in the central nervous system and thus block expression of memory, and (b) a stable modification of adrenergic sites may be involved in the formation and persistence of the memory trace. This view is consistent with the observation mentioned above, that reserpine and alpha-methyl-para-tyrosine, both of which cause reduction of the norepinephrine level, can produce a temporary impairment of the performance of a well-established conditioned avoidance response.
Deutsch has presented experiments which he interprets to indicate that the cholinergic system is involved in memory of maze learning in rats.'5 The involvement of both systems is not inconsistent if it is considered that the adrenergic system acts as a modulator to increase the sensitivity of the cholinergic system or, as proposed by Burn,'6 that acetylcholine is responsible for the release of norepinephrine.
Further experiments are in progress to determine whether the drugs which we have used cause a release of radioactive puromycin peptides from the brain.
